• Je něco špatně v tomto záznamu ?

Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy

E. García-Martínez, M. Smith, A. Buqué, F. Aranda, FA. de la Peña, A. Ivars, MS. Cánovas, MAV. Conesa, J. Fucikova, R. Spisek, L. Zitvogel, G. Kroemer, L. Galluzzi,

. 2018 ; 7 (6) : e1433982. [pub] 20180215

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18023991

Cytokines regulate virtually aspects of innate and adaptive immunity, including the initiation, execution and extinction of tumor-targeting immune responses. Over the past three decades, the possibility of using recombinant cytokines as a means to elicit or boost clinically relevant anticancer immune responses has attracted considerable attention. However, only three cytokines have been approved so far by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, namely, recombinant interleukin (IL)-2 and two variants of recombinant interferon alpha 2 (IFN-α2a and IFN-α2b). Moreover, the use of these cytokines in the clinics is steadily decreasing, mostly as a consequence of: (1) the elevated pleiotropism of IL-2, IFN-α2a and IFN-α2b, resulting in multiple unwarranted effects; and (2) the development of highly effective immunostimulatory therapeutics, such as immune checkpoint blockers. Despite this and other obstacles, research in the field continues as alternative cytokines with restricted effects on specific cell populations are being evaluated. Here, we summarize research preclinical and clinical developments on the use of recombinant cytokines for immunostimulation in cancer patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18023991
003      
CZ-PrNML
005      
20180717102617.0
007      
ta
008      
180709s2018 xxu f 000 0|engg|
009      
AR
024    7_
$a 10.1080/2162402X.2018.1433982 $2 doi
035    __
$a (PubMed)29872569
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a García-Martínez, Elena $u Hematology and Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
245    10
$a Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy / $c E. García-Martínez, M. Smith, A. Buqué, F. Aranda, FA. de la Peña, A. Ivars, MS. Cánovas, MAV. Conesa, J. Fucikova, R. Spisek, L. Zitvogel, G. Kroemer, L. Galluzzi,
520    9_
$a Cytokines regulate virtually aspects of innate and adaptive immunity, including the initiation, execution and extinction of tumor-targeting immune responses. Over the past three decades, the possibility of using recombinant cytokines as a means to elicit or boost clinically relevant anticancer immune responses has attracted considerable attention. However, only three cytokines have been approved so far by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, namely, recombinant interleukin (IL)-2 and two variants of recombinant interferon alpha 2 (IFN-α2a and IFN-α2b). Moreover, the use of these cytokines in the clinics is steadily decreasing, mostly as a consequence of: (1) the elevated pleiotropism of IL-2, IFN-α2a and IFN-α2b, resulting in multiple unwarranted effects; and (2) the development of highly effective immunostimulatory therapeutics, such as immune checkpoint blockers. Despite this and other obstacles, research in the field continues as alternative cytokines with restricted effects on specific cell populations are being evaluated. Here, we summarize research preclinical and clinical developments on the use of recombinant cytokines for immunostimulation in cancer patients.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Smith, Melody $u Department of Medicine and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
700    1_
$a Buqué, Aitziber $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
700    1_
$a Aranda, Fernando $u Immunoreceptors of the Innate and Adaptive System, IDIBAPS, Barcelona, Spain.
700    1_
$a de la Peña, Francisco Ayala $u Hematology and Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
700    1_
$a Ivars, Alejandra $u Hematology and Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
700    1_
$a Cánovas, Manuel Sanchez $u Hematology and Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
700    1_
$a Conesa, Ma Angeles Vicente $u Hematology and Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
700    1_
$a Fucikova, Jitka $u Sotio, Prague, Czech Republic. Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic.
700    1_
$a Spisek, Radek $u Sotio, Prague, Czech Republic. Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic.
700    1_
$a Zitvogel, Laurence $u Gustave Roussy Comprehensive Cancer Institute, Villejuif, France. INSERM, U1015, Villejuif, France. Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France. Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France.
700    1_
$a Kroemer, Guido $u Université Paris Descartes/Paris V, France. Université Pierre et Marie Curie/Paris VI, Paris. Equipe 11 labellisée Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Institute, Villejuif, France. Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden. Pôle de Biologie, Hopitâl Européen George Pompidou, AP-HP, Paris, France.
700    1_
$a Galluzzi, Lorenzo $u Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. Université Paris Descartes/Paris V, France. Sandra and Edward Meyer Cancer Center, New York, NY, USA.
773    0_
$w MED00190079 $t Oncoimmunology $x 2162-4011 $g Roč. 7, č. 6 (2018), s. e1433982
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29872569 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180717102917 $b ABA008
999    __
$a ind $b bmc $g 1315978 $s 1020909
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 7 $c 6 $d e1433982 $e 20180215 $i 2162-4011 $m Oncoimmunology $n Oncoimmunology $x MED00190079
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Možnosti archivace